Reversible Corneal Decompensation Caused by a Topical Dorzolamide/Timolol Fixed Combination After Descemet Stripping Automated Endothelial Keratoplasty
Conclusions:
Topical DTFC should be used with caution after corneal endothelial transplantation because of the possibility of iatrogenic corneal endothelial dysfunction. (Source: Cornea)
Source: Cornea - August 18, 2022 Category: Opthalmology Tags: Case Report Source Type: research
Retraction Note to: Sustained Delivery of Timolol Using Nanostructured Lipid Carriers-Laden Soft Contact Lenses
AAPS PharmSciTech. 2022 Aug 12;23(6):222. doi: 10.1208/s12249-022-02382-x.NO ABSTRACTPMID:35962288 | DOI:10.1208/s12249-022-02382-x (Source: AAPS PharmSciTech)
Source: AAPS PharmSciTech - August 12, 2022 Category: Drugs & Pharmacology Authors: Chenfei Tian Lu Zeng Le Tang Jingni Yu Mei Ren Source Type: research
Retraction Note to: Sustained Delivery of Timolol Using Nanostructured Lipid Carriers-Laden Soft Contact Lenses
AAPS PharmSciTech. 2022 Aug 12;23(6):222. doi: 10.1208/s12249-022-02382-x.NO ABSTRACTPMID:35962288 | DOI:10.1208/s12249-022-02382-x (Source: AAPS PharmSciTech)
Source: AAPS PharmSciTech - August 12, 2022 Category: Drugs & Pharmacology Authors: Chenfei Tian Lu Zeng Le Tang Jingni Yu Mei Ren Source Type: research
Retraction Note to: Sustained Delivery of Timolol Using Nanostructured Lipid Carriers-Laden Soft Contact Lenses
AAPS PharmSciTech. 2022 Aug 12;23(6):222. doi: 10.1208/s12249-022-02382-x.NO ABSTRACTPMID:35962288 | DOI:10.1208/s12249-022-02382-x (Source: AAPS PharmSciTech)
Source: AAPS PharmSciTech - August 12, 2022 Category: Drugs & Pharmacology Authors: Chenfei Tian Lu Zeng Le Tang Jingni Yu Mei Ren Source Type: research
The Use of Beta-Blockers in Hereditary Hemorrhagic Telangiectasia-Related Epistaxis: A Systematic Review
CONCLUSION: There are significant limitations in the included studies, and further investigation with larger longitudinal or randomized prospective trials is recommended. The available evidence suggests that beta-blocker treatment may have a positive effect on HHT-related epistaxis.PMID:35929049 | DOI:10.1177/19458924221118131 (Source: American Journal of Rhinology and Allergy)
Source: American Journal of Rhinology and Allergy - August 5, 2022 Category: ENT & OMF Authors: Hashm Albarki Joanne Rimmer Source Type: research
The Use of Beta-Blockers in Hereditary Hemorrhagic Telangiectasia-Related Epistaxis: A Systematic Review
CONCLUSION: There are significant limitations in the included studies, and further investigation with larger longitudinal or randomized prospective trials is recommended. The available evidence suggests that beta-blocker treatment may have a positive effect on HHT-related epistaxis.PMID:35929049 | DOI:10.1177/19458924221118131 (Source: American Journal of Rhinology and Allergy)
Source: American Journal of Rhinology and Allergy - August 5, 2022 Category: ENT & OMF Authors: Hashm Albarki Joanne Rimmer Source Type: research
The Use of Beta-Blockers in Hereditary Hemorrhagic Telangiectasia-Related Epistaxis: A Systematic Review
CONCLUSION: There are significant limitations in the included studies, and further investigation with larger longitudinal or randomized prospective trials is recommended. The available evidence suggests that beta-blocker treatment may have a positive effect on HHT-related epistaxis.PMID:35929049 | DOI:10.1177/19458924221118131 (Source: American Journal of Rhinology and Allergy)
Source: American Journal of Rhinology and Allergy - August 5, 2022 Category: ENT & OMF Authors: Hashm Albarki Joanne Rimmer Source Type: research
Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment
Adv Ther. 2022 Jun 22. doi: 10.1007/s12325-022-02210-5. Online ahead of print.NO ABSTRACTPMID:35731341 | DOI:10.1007/s12325-022-02210-5 (Source: Adv Data)
Source: Adv Data - June 22, 2022 Category: Epidemiology Authors: Francesco Oddone James Kirwan Fernando Lopez-Lopez Marina Zimina Claudia Fassari G ábor Holló VISIONARY Study Group Source Type: research
Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment
(Source: Advances in Therapy)
Source: Advances in Therapy - June 22, 2022 Category: Drugs & Pharmacology Source Type: research
XEN < sup > ® < /sup > 63 gel stent to treat a refractory uveitic glaucoma: A case report
CONCLUSION: The XEN® 63 gel stent provides a good intraocular pressure reduction and can be an efficient alternative for tube and filtration surgery in refractory glaucoma. Its long-term effectiveness needs to be evaluated.PMID:35711166 | DOI:10.1177/11206721221109199 (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - June 17, 2022 Category: Opthalmology Authors: Yasmine Serrar Amina Rezkallah Laurent Kodjikian Muriel Poli Thibaud Mathis Philippe Denis Source Type: research
XEN < sup > ® < /sup > 63 gel stent to treat a refractory uveitic glaucoma: A case report
CONCLUSION: The XEN® 63 gel stent provides a good intraocular pressure reduction and can be an efficient alternative for tube and filtration surgery in refractory glaucoma. Its long-term effectiveness needs to be evaluated.PMID:35711166 | DOI:10.1177/11206721221109199 (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - June 17, 2022 Category: Opthalmology Authors: Yasmine Serrar Amina Rezkallah Laurent Kodjikian Muriel Poli Thibaud Mathis Philippe Denis Source Type: research
XEN < sup > ® < /sup > 63 gel stent to treat a refractory uveitic glaucoma: A case report
CONCLUSION: The XEN® 63 gel stent provides a good intraocular pressure reduction and can be an efficient alternative for tube and filtration surgery in refractory glaucoma. Its long-term effectiveness needs to be evaluated.PMID:35711166 | DOI:10.1177/11206721221109199 (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - June 17, 2022 Category: Opthalmology Authors: Yasmine Serrar Amina Rezkallah Laurent Kodjikian Muriel Poli Thibaud Mathis Philippe Denis Source Type: research
XEN < sup > ® < /sup > 63 gel stent to treat a refractory uveitic glaucoma: A case report
CONCLUSION: The XEN® 63 gel stent provides a good intraocular pressure reduction and can be an efficient alternative for tube and filtration surgery in refractory glaucoma. Its long-term effectiveness needs to be evaluated.PMID:35711166 | DOI:10.1177/11206721221109199 (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - June 17, 2022 Category: Opthalmology Authors: Yasmine Serrar Amina Rezkallah Laurent Kodjikian Muriel Poli Thibaud Mathis Philippe Denis Source Type: research
XEN < sup > ® < /sup > 63 gel stent to treat a refractory uveitic glaucoma: A case report
CONCLUSION: The XEN® 63 gel stent provides a good intraocular pressure reduction and can be an efficient alternative for tube and filtration surgery in refractory glaucoma. Its long-term effectiveness needs to be evaluated.PMID:35711166 | DOI:10.1177/11206721221109199 (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - June 17, 2022 Category: Opthalmology Authors: Yasmine Serrar Amina Rezkallah Laurent Kodjikian Muriel Poli Thibaud Mathis Philippe Denis Source Type: research
Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension
CONCLUSIONS: The current evidence suggests that in people diagnosed with OHT or (P)OAG, the hypotensive effect of netarsudil may be inferior to latanoprost and slightly inferior to timolol. Combining netarsudil and latanoprost probably further reduces IOP compared with monotherapy. Netarsudil as mono- or combination therapy may result in more ocular AEs. However, the certainty of evidence was very low or low for all comparisons except timolol. In general, AEs were described as mild, transient, and reversible upon treatment discontinuation. ROKi was not associated with any particular serious AEs. Future trials of sufficient...
Source: Cochrane Database of Systematic Reviews - June 10, 2022 Category: General Medicine Authors: Josefine Clement Freiberg Alexander von Spreckelsen Miriam Kolko Augusto Azuara-Blanco Gianni Virgili Source Type: research
